The University of Iowa

Publications

Baseline Results of the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study

Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sankoju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworkski PG, Prior TW, Burghes AHM, Bartlett A, Kissell JT & the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators
Annals of Clinical and Translational Neurology. 2016; 3 (2) 132-145.
PubMed: 

CSF Biomarkers Associated with Disease Heterogeneity in Early Parkinson’s Disease: The Parkinson’s Progression Marker’s Initiative Study

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligorska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Keiburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, & Shaw LM on behalf of the Parkinson’s Progression Markers Initiative
Acta Neuropathologica. 2016; 131 (6) 935-949.

Design, Rationale, and Baseline Characteristics of the Randomized Double-Blind Phase II Clinical Trial of Ibudilast in Progressive Multiple Sclerosis

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman, A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, WeinstockGutman B, Yadav V, & Zabeta A
Contemporary Clinical Trials. 2016; 50 166-177.
PubMed: